Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5701071 | European Journal of Surgical Oncology (EJSO) | 2017 | 7 Pages |
Abstract
CNB showed good accuracy in evaluating hormonal receptors status, HER2, and BC molecular subtypes. Evaluation of Ki67 status was less accurate than other biomarkers; therefore, we recommend that it should be detected both on CNB and SS samples, especially in hormonal positive HER2 negative tumors, in order to avoid a misclassification of tumor subtypes that could lead to an omission of potential effective systemic therapy.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
I. Meattini, G. Bicchierai, C. Saieva, D. De Benedetto, I. Desideri, C. Becherini, D. Abdulcadir, E. Vanzi, C. Boeri, S. Gabbrielli, F. Lucci, L. Sanchez, D. Casella, M. Bernini, L. Orzalesi, V. Vezzosi, D. Greto, M. Mangoni, J. Nori,